Ranbaxy's Anti-Malarial Approval Makes It First Indian Firm To Fully Develop An NCE
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For Ranbaxy Laboratories Ltd., it has been nearly a decade-long bumpy ride to discover and develop its anti-malarial compound, but India's regulator - the Drug Controller General of India - finally granted the company a conditional approval to market the compound
You may also be interested in...
Sneak Preview: Clinical Trial Policies Top IP As Biggest Obstacle To Indian Innovation
Despite recent news flow focused on a challenging patent environment, India’s pharma market is expected to grow 13% annually to reach $45 billion by 2020, according to a McKinsey report to be released June 21 during the annual U.S.-India BioPharma & Healthcare Summit in Boston.
Ranbaxy Records $568 Million Loss For DoJ Penalty; Sees More Predictability In U.S. Business
India’s Ranbaxy has reported mixed results as it tops $2 billion in sales but suffers $568 million in losses from a U.S. consent decree penalty.
Ranbaxy Records $568 Million Loss For DoJ Penalty; Sees More Predictability In U.S. Business
India’s Ranbaxy has reported mixed results as it tops $2 billion in sales, but suffers $568 million in losses from a U.S. consent decree penalty.